Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Adherence (medicine) wikipedia , lookup
Compounding wikipedia , lookup
Environmental persistent pharmaceutical pollutant wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Pharmaceutical marketing wikipedia , lookup
Environmental impact of pharmaceuticals and personal care products wikipedia , lookup
pg 1/2 March 18, 2009 DUCHESNAY RELEASES A COMPLETE PRODUCT MONOGRAPH FOR PREGVIT/PREGVIT FOLIC 5 Duchesnay brings forward significant innovation by releasing the first complete Product Monograph for the safe and effective use of pre/postnatal supplements. The scientific literature reports many examples of vitamin/mineral-drug interactions. For example, calcium and iron interaction with thyroid hormone products such as levothyroxine has been well documented. In addition to showing a detailed description of product indications and properties, the PregVit/PregVit folic 5 Product Monograph provides fully referenced clinical trial data, drug interaction summary and individualized dosing and administration information. PregVit/PregVit folic 5 Product Monograph is available on http://monograph.pregvit.com. To receive a paper copy, send an e-mail to: [email protected]. PregVit® and PregVit folic 5® are available at all wholesalers. PRODUCTS DIN UPC PregVit® 02246067 7 79943 00021 PregVit folic 5® 02276194 7 79943 00061 Pr Pr Duchesnay: 1.888.666.0611 ([email protected]) NEORAL*(CYCLOSPORINE) 10 MG, 25 MG, 50 MG, 100 MG CAPSULES FREE CLASSIFIED ADVERTISING FOR PHARMACISTS FAX : 1-800-420-3616 EMAIL: [email protected] Effective mid-February 2009, Novartis Pharmaceuticals Canada Inc. will be implementing changes to the appearance of all Neoral capsule strengths. The current “S” embedded in a triangle marking will be replaced with an updated “NVR” marking. This change is expected to be fully implemented for all strengths by May 2009. This change only affects the capsule appearance and does not affect either the formulation, capsule size, packaging and/or product label/prescribing information. For any questions concerning this change or correspondence, please contact Novartis Pharmaceuticals Canada Inc. Medical Information at 1-800-363-8883. Pr Neoral* Cyclosporine Capsules 10 mg 25 mg 50 mg 100 mg *Neoral is a registered trademark. © Novartis Pharmaceuticals Canada Inc. Visit us at www.ipharmadirect.com DIN 02237671 02150689 02150662 02150670 pg 2/2 March 18, 2009 ZYBAN® UPDATE COMBIGAN 10ML OPHTHALMIC SOLUTION CONTINUES TO BE AVAILABLE FOR ORDERING Combigan 10mL ophthalmic solution continues to be available for ordering. The price per ml remains unchanged for the 10mL. Combigan 10mL is fully covered under all provincial formulary plans. Although Combigan 5mL is unavailable, it is recommended that you order Combigan 10mL ophthalmic solution. Product UPC PM# Combigan 10 mL ophthalmic Solution 0 69886-92112 0 92112EC Should you require further information, please do not hesitate to contact our Customer Service at 1-800-668-6477. FREE CLASSIFIED ADVERTISING FOR PHARMACISTS/ GRATUITS POUR PHARMACIENS L’ÉCHANGE PHARMACIEN À PHARMACIEN® FAX / TÉLÉCOPIEUR SANS FRAIS: 1-800-420-3616 EMAIL / COURRIEL: The seizure rate associated with doses of bupropion SR up to 300 mg/day is approximately 0.1%. Please refer to the Zyban® Product Monograph for complete dosing information. CATEGORY / CATÉGORIE • • • • • There are clinical trials and post-marketing reports with SSRIs and other newer anti-depressants, in both pediatrics and adults, of severe agitationtype adverse events coupled with self-harm or harm to others. The agitation-type events include: akathisia, agitation, disinhibition, emotional lability, hostility, aggression, depersonalization. In some cases, the events occurred within several weeks of starting treatment. Given that bupropion may be prescribed as either an anti-depressant (Wellbutrin® SR/Wellbutrin® XL) or a smoking cessation product (Zyban®), these findings affect the conditions of use of all these products.1 Agitation-type changes are reported for Zyban®, and monitoring for these indicators of potential suicidal behaviour is advised in patients of all ages given a newer anti-depressant drug, including bupropion. When reported in patients undergoing a smoking cessation attempt, such changes may be a symptom of nicotine withdrawal, along with depressed mood and related symptoms, such as difficulty concentrating and anxiety.1 [email protected] • • • • The most commonly observed adverse events in patients treated with Zyban® are dry mouth (11%, compared with 5% in patients taking placebo) and insomnia (31% vs. 21% with placebo). The risk of insomnia may be reduced by avoiding bedtime doses.1 Career Opportunities / Perspectives de carrière Pharmacy for Sale / Pharmacie à vendre Pharmacy Wanted / Pharmacie demandée For Sale - Pharmacy Store/Equipment / À vendre - Équipement de pharmacie Pharmacist Available / Pharmacien - disponible Vacation Spots / Endroits de vacances Seminars / Courses / Conférences et séminaires For Sale - Miscellaneous / À vendre - divers Other / Autre Flexible to maximize patient sample initiations Offers multiple formats to leverage any promotion Guarantees a return on investment Lowers the cost of delivering patient samples Increases the safety and integrity of your drug samples Extends the reach beyond your current target physicians The most recent version of the Zyban® Product Monograph is available upon request. Should you have any questions, please call Biovail Medical Information at 1-866-825-8120 or e-mail us at [email protected]. References: 1 Zyban® (bupropion HCl) Product Monograph, Biovail Pharmaceuticals Canada, February 2009. Pharmacist Information Biovail Pharmaceuticals Canada would like to ensure that patients who are prescribed Zyban® (bupropion hydrochloride) for smoking cessation receive the most up-to-date information pertaining to the safety and tolerability of this medication, in accordance with the recently updated Product Monograph. What topics would you like to see covered in potential future editorial stories? • • • • • • • • Reducing your taxes Managing staff Store security Privacy laws Internet dispensing Consumer counseling Inventory management CHE requirements ________ ________ ________ ________ ________ ________ ________ ________ Please fax to: 1-800-420-3616